HUE043122T2 - Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk - Google Patents

Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk

Info

Publication number
HUE043122T2
HUE043122T2 HUE15706282A HUE15706282A HUE043122T2 HU E043122 T2 HUE043122 T2 HU E043122T2 HU E15706282 A HUE15706282 A HU E15706282A HU E15706282 A HUE15706282 A HU E15706282A HU E043122 T2 HUE043122 T2 HU E043122T2
Authority
HU
Hungary
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
HUE15706282A
Other languages
English (en)
Hungarian (hu)
Inventor
Alexander Bondke
Sebastian Kroll
Anthony Barrett
Matthew Fuchter
Brian Slafer
Simak Ali
Charles Coombes
James Patrick Snyder
Original Assignee
Cancer Research Tech Ltd
Ip2Ipo Innovations Ltd
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Ip2Ipo Innovations Ltd, Univ Emory filed Critical Cancer Research Tech Ltd
Publication of HUE043122T2 publication Critical patent/HUE043122T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE15706282A 2014-02-21 2015-02-20 Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk HUE043122T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use

Publications (1)

Publication Number Publication Date
HUE043122T2 true HUE043122T2 (hu) 2019-08-28

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15706282A HUE043122T2 (hu) 2014-02-21 2015-02-20 Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk

Country Status (23)

Country Link
US (4) US9932344B2 (en, 2012)
EP (1) EP3107914B8 (en, 2012)
JP (1) JP6498212B2 (en, 2012)
CN (1) CN106103445B (en, 2012)
AU (1) AU2015220560B2 (en, 2012)
BR (1) BR112016018633B1 (en, 2012)
CA (1) CA2939786C (en, 2012)
CY (1) CY1121588T1 (en, 2012)
DK (1) DK3107914T3 (en, 2012)
ES (1) ES2721268T3 (en, 2012)
GB (1) GB201403093D0 (en, 2012)
HR (1) HRP20190685T1 (en, 2012)
HU (1) HUE043122T2 (en, 2012)
LT (1) LT3107914T (en, 2012)
ME (1) ME03427B (en, 2012)
NZ (1) NZ724323A (en, 2012)
PL (1) PL3107914T3 (en, 2012)
PT (1) PT3107914T (en, 2012)
RS (1) RS58704B1 (en, 2012)
SI (1) SI3107914T1 (en, 2012)
SM (1) SMT201900266T1 (en, 2012)
TR (1) TR201905647T4 (en, 2012)
WO (1) WO2015124941A1 (en, 2012)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2966164C (en) 2014-10-31 2023-10-17 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
CA2970574C (en) 2014-12-17 2023-09-19 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rar.beta.) agonists
CA2976109A1 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors
EP3309163A4 (en) 2015-06-15 2019-01-09 UBE Industries, Ltd. SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
US20200123499A1 (en) 2015-12-02 2020-04-23 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
EP3507290A1 (en) 2016-08-31 2019-07-10 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
EP4438117A3 (en) 2017-07-28 2024-12-18 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
MX2020001531A (es) * 2017-08-07 2020-03-20 Biocad Joint Stock Co Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
IL277770B2 (en) * 2018-04-11 2024-01-01 Qurient Co Ltd Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
MX2020014245A (es) 2018-06-29 2021-05-12 Kinnate Biopharma Inc Inhibidores de quinasas dependientes de ciclinas.
IL282254B1 (en) * 2018-10-30 2025-04-01 Kronos Bio Inc Compounds, compositions, and methods for modulating CDK9 activity
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
CN109860354B (zh) 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
WO2021003517A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
JP2023517034A (ja) * 2020-03-06 2023-04-21 バイエル アクチェンゲゼルシャフト Cdk12の阻害を介してがんに作用するイミダゾトリアジン
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022156779A1 (zh) * 2021-01-22 2022-07-28 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物、其组合物及医药上的用途
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
KR20240110634A (ko) * 2021-11-24 2024-07-15 크로노스 바이오, 인코포레이티드 (1s,3s)-n1-(5-(펜탄-3-일)피라졸로[1,5-a]피리미딘-7-일)시클로펜탄-1,3-디아민의다형체 및 염 형태
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
WO2024174949A1 (zh) * 2023-02-20 2024-08-29 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
WO2024175024A1 (zh) * 2023-02-21 2024-08-29 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202500147A (zh) 2023-06-27 2025-01-01 美商亞文納營運公司 雌激素受體降解劑與cdk7抑制劑之組合
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457201A (en) 1999-12-28 2001-07-09 Bristol-Myers Squibb Company Cytokine, especially tnf-alpha, inhibitors
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
EP2170073A4 (en) 2007-06-05 2011-07-27 Univ Emory SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
SG181507A1 (en) 2009-12-04 2012-07-30 Cylene Pharmaceuticals Inc Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
EP3812387A1 (en) * 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
DK3107914T3 (en) 2019-04-29
LT3107914T (lt) 2019-05-27
AU2015220560A1 (en) 2016-10-06
EP3107914B1 (en) 2019-01-30
CN106103445B (zh) 2019-08-09
NZ724323A (en) 2022-02-25
US20180273540A1 (en) 2018-09-27
CN106103445A (zh) 2016-11-09
ES2721268T3 (es) 2019-07-30
JP6498212B2 (ja) 2019-04-10
TR201905647T4 (tr) 2019-05-21
EP3107914A1 (en) 2016-12-28
US10927119B2 (en) 2021-02-23
RS58704B1 (sr) 2019-06-28
BR112016018633B1 (pt) 2022-08-30
US11566029B2 (en) 2023-01-31
US20210253583A1 (en) 2021-08-19
WO2015124941A1 (en) 2015-08-27
EP3107914B8 (en) 2019-07-17
CA2939786A1 (en) 2015-08-27
ME03427B (me) 2020-01-20
US20160362410A1 (en) 2016-12-15
CA2939786C (en) 2022-03-08
US9932344B2 (en) 2018-04-03
BR112016018633A2 (en, 2012) 2017-08-08
HRP20190685T1 (hr) 2019-06-14
GB201403093D0 (en) 2014-04-09
US10414772B2 (en) 2019-09-17
US20200055862A1 (en) 2020-02-20
JP2017506250A (ja) 2017-03-02
PT3107914T (pt) 2019-05-20
SI3107914T1 (sl) 2019-05-31
AU2015220560B2 (en) 2019-05-16
CY1121588T1 (el) 2020-05-29
PL3107914T3 (pl) 2019-09-30
SMT201900266T1 (it) 2019-07-11

Similar Documents

Publication Publication Date Title
HUE043122T2 (hu) Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk
FR22C1058I1 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
IL247949A0 (en) New histories of pyrazolopyrimidines and their use as malt1 inhibitors
EP3500575A4 (en) CRYSTALLINE FORM OF (S) -7- (1-ACRYLOYLPIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRA-HYDROPYRAZOLO [1,5-A] PYRIMIDINE-3-CARBOXAMIDE , ITS PREPARATION AND ITS USES
HK1245247A1 (zh) 溴結構域的抑制劑
HUE037558T2 (hu) Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
HUE051067T2 (hu) N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HUE053376T2 (hu) Poliuretánok elõállításában történõ alkalmazásra megfelelõ, nitrogént tartalmazó vegyületek
DK3288942T3 (da) Rsv-antivirale pyrazolo- og triazolopyrimidinforbindelser
HUE050320T2 (hu) PDE1 inhibitor 1,5-dihidro-4H-pirazolo[3-4-d]pirimidin-4-onok és 1,5-dihidro-4H-pirazolo[3-4-d]piridin-4-onok
EP3722298A4 (en) PYRROLO DERIVATIVE (PYRAZOLO) PYRIMIDINE USED AS LRRK2 INHIBITOR
LT3532067T (lt) Liposominė vaisto forma, skirta naudoti gydant vėžį
PL3310784T3 (pl) Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
EP3197898A4 (en) Novel imidazopyridazine compounds and their use
HRP20180788T1 (hr) [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases